美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Marizyme, Inc.

0.0000

0.0000

成交量：- -

成交額：- -

市值：131.79

市盈率：0.00

高：0.0000

開：0.0000

低：0.0000

收：0.0000

52周最高：0.0081

52周最低：0.0000

股本：1.32億

流通股本：6,100.70萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.1349

每股收益(LYR):-1.4370

淨資產收益率：-3137.71%

總資產收益率：-26.57%

市淨率：-0.00

市盈率(LYR):NaN

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Marizyme, Inc.

交易所：

EXPERT

成立時間：

2007

員工人數：

13

公司地址：

555 Heritage Drive,Suite 205,Jupiter,Florida,United States

官網：

http://www.marizyme.com

郵編：

33458

電話：

傳真：

- -

簡介：

Marizyme, Inc.於2007年3月20日在內華達州註冊成立。該公司是一家多技術生命科學公司，致力於加速、開發和商業化促進患者健康並呈現快速收入增長潛力的醫療技術。該公司專註於開發三個醫療技術平台——DuraGraft、MATLOC和Krillase——每個平台都經過臨床測試，並由專利或正在申請專利的資產組合提供支持。DuraGraft是一種一次性的術中血管移植治療，能夠保護內皮細胞免受缺血性損傷和再灌注損傷，並減少CABG后與VGF相關的併發症，從而減少重複血運重建和心肌梗死等主要心臟不良事件，減少移植失敗的發生率和併發症，並改善臨床結果。MATLOC是用於CKD評估的床旁、片上實驗室数字篩查和診斷設備平台。該公司的Krillase蛋白酶為傷口癒合、血栓形成和寵物健康提供治療。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/MRZM/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MRZM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRZM\",,,,,undefined,":{"symbol":"MRZM","market":"US","secType":"STK","nameCN":"Marizyme, Inc.","latestPrice":0.000001,"timestamp":1774555200000,"preClose":0.000001,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":61006967,"shares":131793088,"eps":-0.134879,"marketStatus":"盤後交易","change":0,"latestTime":"03-26 16:00:00 EDT 延時","open":0.000001,"high":0.000001,"low":0.000001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.134879,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1774569600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.000001,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRZM\",,,,,undefined,":{"symbol":"MRZM","floatShares":61006967,"roa":"-26.57%","roe":"-3137.71%","lyrEps":-1.437042,"shares":131793088,"dividePrice":0,"high":0.000001,"amplitude":0,"preClose":0.000001,"low":0.000001,"week52Low":0.000001,"pbRate":"-0.00","psRate":"0.00","week52High":0.0081,"institutionHeld":0,"latestPrice":0.000001,"eps":-0.134879,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.134879,"open":0.000001,"prevYearClose":0.000001,"prevWeekClose":0,"prevMonthClose":0,"prevQuarterClose":0,"fiveDayClose":0,"twentyDayClose":0,"sixtyDayClose":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MRZM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-14","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-28","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1716868800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-13","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-08-18","symbol":"MRZM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1692331200000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MRZM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MRZM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":38038239,"yearFounded":2007,"employeeNum":13,"address":"555 Heritage Drive,Suite 205,Jupiter,Florida,United States","zipCode":"33458","officePhone":"561 935 9955"},"stockCompanyDetail":{"websiteUrl":"http://www.marizyme.com","description":"Marizyme, Inc.於2007年3月20日在內華達州註冊成立。該公司是一家多技術生命科學公司，致力於加速、開發和商業化促進患者健康並呈現快速收入增長潛力的醫療技術。該公司專註於開發三個醫療技術平台——DuraGraft、MATLOC和Krillase——每個平台都經過臨床測試，並由專利或正在申請專利的資產組合提供支持。DuraGraft是一種一次性的術中血管移植治療，能夠保護內皮細胞免受缺血性損傷和再灌注損傷，並減少CABG后與VGF相關的併發症，從而減少重複血運重建和心肌梗死等主要心臟不良事件，減少移植失敗的發生率和併發症，並改善臨床結果。MATLOC是用於CKD評估的床旁、片上實驗室数字篩查和診斷設備平台。該公司的Krillase蛋白酶為傷口癒合、血栓形成和寵物健康提供治療。","exchange":"EXPERT","name":"Marizyme, Inc.","nameEN":"Marizyme, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"MRZM\",market:\"US\",,,undefined,":null}}